Skip to main content
SpringerLink
Log in

Risk-Benefit Assessment of Newer Versus Older Monoamine Oxidase (MAO) Inhibitors

  • Review Article
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

The first generation of monoamine oxidase (MAO) inhibitors fell into disuse because of poor efficacy in major depression with melancholia and/or endogenous depression, and because of poor tolerability (drug interactions and the ‘cheese’ effect). New MAO inhibitors, reversible inhibitors of MAO-A (RIMAs), are able to induce a reversible and specific inhibition of MAO-A. Consequently, the inhibition of MAO is quicker and the dose-response relationship improved, such that dosage adjustment is easier. Also, no carry-over effect once treatment is terminated is observed. The frequency and severity of drug interactions with RIMAs is reduced, although coadministration with pethidine (meperidine) or dextromethorphan should still be avoided.

No specific subgroup of patients with depression has shown a better or worse response to RIMAs. The presence of melancholia in major depression, or the existence of endogenous depression, are not predictive of reduced efficacy compared with tricyclic antidepressant (TCA) reference compounds. Dysthymic patients have shown a good response to both RIMAs and TCAs independent of the co-existence of a major depressive episode. Older MAO inhibitors are more effective than TCAs in the treatment of atypical depression, and further studies are needed to confirm if this is true for RIMAs. Long term studies to evaluate the effects of RIMAs on disease recurrence are also required.

RIMAs are better tolerated than older MAO inhibitors, including use in subgroups particularly at risk of adverse effects such as the elderly. Overall, RIMAs appear to represent therapeutic progress in the treatment of depression in terms of both efficacy and tolerability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Amrein R, Guntert TW, Dingemanse J, Lorscheid T, Stabl M, et al. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology 106 (Suppl.): 24–31, 1992

    Article  Google Scholar 

  • Angst J. Antidepressiver Effekt und genetische Faktoren. Arzneimittel-Forschung 14 (Suppl.): 496–500, 1964

    PubMed  CAS  Google Scholar 

  • Barrelet L, Blajev B, Bolzani L, de Saussure C, Kasas A, et al. Multicentre study comparing the efficacy and tolerability of moclobemide and fluvoxamine in hospitalized patients and in outpatients presenting with a major depressive episode. Schweizerische Rundschau für Medizin Praxis 80: 524–528, 1991

    PubMed  CAS  Google Scholar 

  • Baumhackl U, Biziere K, Fisbach R, Geretsegger CH, Hebenstreit G, et al. Efficacy and tolerability of oclobemide compared with imipramine in depressive disorders (DSMIII): an Austrian double blind multicenter study. British Journal of Psychiatry 155 (Suppl. 6): 78–83, 1989

    Google Scholar 

  • Benedetti MS, Rovei V, Dencker SJ, Nagy A, Johansson R. Pharmacokinetics of toloxatone in man following intravenous and oral administration. Arzneimittel-Forschung 32: 276–280, 1982

    PubMed  CAS  Google Scholar 

  • Bennett IF. Is there a superior antidepressant? Proceedings of the Fifth International Congress of the CINP, pp. 375–393, 1967

  • Berlin I, Zimmer R, Payan C, Thiede HM, Robin L, et al. Comparison of the inhibition of the monoamine oxidase by two reversible IMAO, moclobemide and toloxatone. Study of their effect on memory and vigilance. European Journal of Pharmacology 183: 531,1990

    Article  Google Scholar 

  • Bougerol T, Uchida C, Gachoud JP, Kohler M, Mikelsen H. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). French/Swiss double-blind trial Psychopharmacology 106 (Suppl.): 102–108, 1992

    Article  Google Scholar 

  • British Medical Research Council. Clinical trial of the treatment of depressive illness. British Medical Journal 1: 881–886, 1965

    Article  Google Scholar 

  • Carl G, Laux G. Moclobemide in long-term treatment of depression. Psychiatrische Praxis 17: 26–29, 1990

    Google Scholar 

  • Carrier E, Lang F, Pellet J. Mécanismes d’action supposés des antidépresseurs. Hypothèse biochimique. Actualités Psychiatriques 4: 147–157, 1982

    Google Scholar 

  • Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, et al. Neurochemical profile of moclobemide, a short acting and reversible inhibitor of monoamine oxidase type A. Journal of Clinical and Experimental Therapeutics 248: 400–414, 1989

    Google Scholar 

  • Davidson JRT, Giller EL, Zisook S, Overall JE. An efficacy study of isocarboxazid and placebo in depression and its relationship to depressive nosology. Archives of General Psychiatry 45: 120–127, 1988

    Article  PubMed  CAS  Google Scholar 

  • Davidson JRT, McLeod MN, Turnbull CD, Miller RD. A comparison of phenelzine and imipramine in depressed inpatients. Journal of Clinical Psychiatry 42: 395–397, 1981

    PubMed  CAS  Google Scholar 

  • Ferrey G, Rovei V, Strolin Benedetti M, Gomeni C Languillat JM. Antidepressant activity of toloxatone, a selective MAO-A inhibitor, in depressed patients. In Burrows et al. Eds) Clinical and pharmacological studies in psychiatric disorders, John Libbey, London, 1985

    Google Scholar 

  • Gander DR. Treatment of depressive illnesses with combined antidepressants. Lancet 2: 107, 1965

    Article  Google Scholar 

  • Geerts S, Bruynooghe F, Demeulemeester F, De Cuyper H, Haazen L. Moclobemide vs fluoxetine for a major depressive episode. Clinical Neuropharmacology 15: 420B, 1992

    Article  Google Scholar 

  • Goldberg RS, Thornton WE. Combined tricyclic MAOI therapy for refractory depression: a review with guidelines for appropriate usage. Journal of Clinical Pharmacology 18: 143–147, 1978

    PubMed  CAS  Google Scholar 

  • Guelfi JD, Von Frenckell R, Caille Ph. Essai comparatif en double insu de la toloxatone versus placebo versus amineptine chez 632 patients présentant une asthénie isolée. Mise en évidence des propriétés stimulantes de la toloxatone. L’Information psychiatrique no. special (Humoryl), 1992

  • Guelfi JD, Payan C, Fermanian J, Pedarriosse A, Manfredi R. Moclobemide versus clomipramine in endogenous depression. British Journal of Psychiatry 160: 519–524, 1992

    Article  PubMed  CAS  Google Scholar 

  • Guelfi JD, Favre JD, Von Frenckell R, Caille Ph. Essai comparatif en double insu de la toloxatone versus viloxazine chez 164 patients présentant une dysthymie. L’Information psychiatrique n° special (Humoryl), 1992

  • Himmelhoch JM, Detre T, Kupper DJ, et al. Treatment of previously intractable depressions with tranylxypromine and lithium. Journal of Nervous and Mental Disease 15: 216–220, 1972

    Google Scholar 

  • Himvich WA. Interaction of MAOIs with imipramine and similar drugs. Recent Advances in Biological Psychiatry 4: 257–265,1961

    Google Scholar 

  • Kay DWK, Garside RK, Fahy TJ. A double-blind trial of phenelzine and amitryptyline in depressed outpatients: a possible differential effect on the drugs and symptoms. British Journal of Psychiatry 123: 63–67, 1973

    Article  PubMed  CAS  Google Scholar 

  • Kiloh LG, Child JP, Latner G. A controlled trial of iproniazid in the treatment of endogenous depression. Journal of Mental Science 106: 1139–1144, 1960

    PubMed  CAS  Google Scholar 

  • Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 5: 397–408, 1964

    Article  PubMed  CAS  Google Scholar 

  • Klein DF, Davis J. Diagnosis and drug treatment of psychiatric disorders, William & Wilkins Baltimore, 1968

    Google Scholar 

  • Klein DF, Gittelman-Klein R, Quitkin F, Rifkin A. Diagnosis and drug treatment of psychiatric disorders, William & Wilkins, Baltimore, 1980

    Google Scholar 

  • Koulu M, Schein M, Kaartinen A, Kallio J, Pyykko K, et al. Inhibition of monoamine oxidase by moclobemide: effects of monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. British Journal of Clinical Pharmacology 27: 243–255, 1989

    Article  PubMed  CAS  Google Scholar 

  • Lader M. Combined use of TCAs and MAOIs. Journal of Clinical Psychiatry 44: 20–24, 1983

    PubMed  CAS  Google Scholar 

  • Lecrubier Y, Simon P. IMAO + imipraminiques cette association interdite peut-elle être défendue? La Revue de Médecine 34:2194–2200, 1973

    Google Scholar 

  • Lecrubier Y, Guelfi JD. Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression. Acta Psychiatrica Scandinavica (Suppl. 360): 18–23, 1990

    Google Scholar 

  • Lemoine P, Mirabaud C. A double-blind comparison of moclobemide and toloxatone in out-patients presenting a major depressive disorder. Psychopharmacology 106 (Suppl.): 118–119, 1992

    Article  Google Scholar 

  • Lepine JP. Essai clinique multicentrique randomisé en double insu toloxatone versus fluoxetine dans les dysthymies du DSM III-R en médecine ambulatoire. L’information psychiatrique no. spécial Humoryl, 1992

  • Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, et al. Psychopharmacologic validation of atypical depression. Journal of Clinical Psychiatry 45: 22–25, 1984

    PubMed  CAS  Google Scholar 

  • Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, et al. Antidepressant specificity in atypical depression. Archives of General Psychiatry 45: 129–137, 1988

    Article  PubMed  CAS  Google Scholar 

  • McGrath PJ, Quitkin FM, Harrison W, Stewart J. Treatment of melancholia with tranylcypromine. American Journal of Psychiatry 141:288–289, 1984

    PubMed  CAS  Google Scholar 

  • Nierenberg AA, Reck PE. Management of MAOI-associated insomnia with trazodone. Journal of Clinical Psychopharmacology 9: 42–45, 1989

    Article  PubMed  CAS  Google Scholar 

  • Pare CM. The present status of MAOI. British Journal of Psychiatry 146: 576–584, 1985

    Article  PubMed  CAS  Google Scholar 

  • Pare CMB, Rees L, Sainsbury MJ. Differentiation of two genetically specific types of depression by the response to antidepressants. Lancet 2: 1840–1843, 1962

    Google Scholar 

  • Paykel ES, Parker RR, Penrose RJJ, Rassaby E. Depressive classification and prediction of response to phenelzine. British Journal of Psychiatry 134: 572–581, 1979

    Article  PubMed  CAS  Google Scholar 

  • Paykel ES, Rowan PR, Parker RR, Bhat AV. Response to phenelzine and amitriptyline in depressed outpatients. Archives of General Psychiatry 39: 1041–1049, 1982

    Article  PubMed  CAS  Google Scholar 

  • Quitkin FM, McGrath P, Liebowitz MR, Stewart J, Alfreda H. Monoamine Oxidase Inhibitors in Bipolar Endogenous Depressives. Journal of Clinical Psychopharmacology 1: 70–74, 1981

    Article  PubMed  CAS  Google Scholar 

  • Quitkin FM, Stewart JW, McGrath PJ, Lievoitz MR, Harrison WM, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. American Journal of Psychiatry 14: 306–311, 1988

    Google Scholar 

  • Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P. Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study. Journal of Clinical Psychopharmacology 4: 270–278, 1984

    Article  PubMed  CAS  Google Scholar 

  • Raskin A, Schulterbrandt J, Reatig N, Crook T. Depression subtypes and response to phenelzine, diazepam and a placebo. Archives of General Psychiatry 30: 66–75, 1974

    Article  PubMed  CAS  Google Scholar 

  • Ravaris CL, Nies A, Robinson DS. A multiple-dose controlled study of phenelzine in depression-anxiety states. Archives of General Psychiatry 33: 347–350, 1976

    Article  PubMed  CAS  Google Scholar 

  • Riise IS, Holm P. Concomitant isocarboxamid-mianserin treatment of major depressive disorder. Journal of Affective Disorders 6: 175–179, 1984

    Article  PubMed  CAS  Google Scholar 

  • Roger M, Meignan S, Decup D, Bizein MF, Fanon JL, et al. Essai multicentrique côntrolé en double insu toloxatone versus mianserine chez des sujets âgés présentant une dépression majeure. Synapse 68: 68–75, 1992

    Google Scholar 

  • Rossel L, Moll E. Moclobemide versus tranylcypromine in the treatment of depression. Acta Psychiatrica Scandinavica (Suppl. 360): 61–62, 1990

  • Schoerlin MP, Guentert TW. Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human. Psychiatrische Praxis 16 (Suppl. 1): 11–17, 1989

    PubMed  Google Scholar 

  • Shopsin B. Tricyclics and MAOIs: rational polypharmacy in treatment of resistant depression. Proceedings of the Tenth International Congress of the CINP, Quebec, Canada, July 1976

  • Smith RL, Marsh MV, Dedieu M, Strolin Benedetti M. Interaction of reversible and irreversible monoamine oxidase inhibitors with the drug metabolizing enzymes. In Dostert & Strolin Benedetti (Eds) Monoamine oxidase and disease, pp. 517–526, Academic Press, Tipton, 1984

    Google Scholar 

  • Spitzer RL, Endicott J, Robins E. Research diagnostic criteria rationale and reliability. Archives of General Psychiatry 35: 773–782, 1978

    Article  PubMed  CAS  Google Scholar 

  • Stabl M, Biziere K, Schmid-Burgk W. Review of comparative trials: moclobemide vs tricyclic antidepressants and vs placebo in depressive states. Journal of Neural Transmission 285: 1989

  • Stack CG, Rogers P, Linter SPK. Monoamine oxidase inhibitors and anaesthesia. A review. British Journal of Anaesthesia 60: 222–227, 1988

    Article  PubMed  CAS  Google Scholar 

  • Versiani M, Nardi AE. RIMAs in the treatment of Dysthymia. Proceedings of the Fifth International Congress of the ECNP, 18–22 October, Marbella, 1992

  • Versiani M, Oggero U, Alterwain P, et al. A double blind comparative trial of moclobemide versus imipramine and placebo in major depressive episodes. British Journal of Psychiatry 155 (Suppl. 6): 72–77, 1989

    Google Scholar 

  • Versiani M, Nardi AE, Figueira ILV, Stabl M. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatrica Scandinavica (Suppl. 360): 21–28, 1990

  • West ED, Dally PJ. Effect of iproniazid in depressive syndromes. British Medical Journal 1: 1491–1494, 1959

    Article  PubMed  CAS  Google Scholar 

  • Williams R, Edwards RA. Newburn GM, Mullen R, Menkes DB, et al. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. Internationa; Clinical Psychopharmacology 7: 155–158, 1993

    Article  CAS  Google Scholar 

  • Zetim M. Combined use of trazodone and phenelzine in depression: case report. Journal of Clinical Psychiatry 45: 182–183, 1984

    Google Scholar 

  • Zimmer R. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors. Acta Psychiatrica Scandinavica (Suppl. 360): 81–83, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Directeur de Recherche, INSERM U 302, Hôpital de la Salpetrière, 47 bid de l’Hôpital, 75013, Paris, France

    Yves Lecrubier

Authors
  1. Yves Lecrubier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lecrubier, Y. Risk-Benefit Assessment of Newer Versus Older Monoamine Oxidase (MAO) Inhibitors. Drug-Safety 10, 292–300 (1994). https://doi.org/10.2165/00002018-199410040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199410040-00003

Keywords

Search

Navigation